Cocrystal Pharma, Inc. (COCP) stock
COCPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.98−0.00 (-0.24%)
Close on Nov 16, 2026Market cap $18.83MP/E –Yield –
Cocrystal Pharma r&d expenses
Research and development expenses are spending on new products and technology.
Cocrystal Pharma's R&D Expenses for the twelve months ending Jun 30, 2026 was $6.09M, down 21.6% year over year. For fiscal 2025 it was $5.06M, down 59.7% from the year before. Over ten years it grew -20.0% a year on average. The highest annual figure on record is $101.68M in fiscal 2016.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.06M | -59.7% |
| FY2024 | Dec 31, 2024 | $12.54M | -17.4% |
| FY2023 | Dec 31, 2023 | $15.17M | +22.4% |
| FY2022 | Dec 31, 2022 | $12.39M | +40.9% |
| FY2021 | Dec 31, 2021 | $8.79M | +45.7% |
| FY2020 | Dec 31, 2020 | $6.03M | +50.7% |
| FY2019 | Dec 31, 2019 | $4.00M | -14.2% |
| FY2018 | Dec 31, 2018 | $4.67M | -19.8% |
| FY2017 | Dec 31, 2017 | $5.82M | -94.3% |
| FY2016 | Dec 31, 2016 | $101.68M | +115.1% |
| FY2015 | Dec 31, 2015 | $47.26M | +1060.9% |
| FY2014 | Dec 31, 2014 | $4.07M | +5.4% |
| FY2013 | Dec 31, 2013 | $3.86M | +689.2% |
| FY2012 | Dec 31, 2012 | $489.35K | +15.6% |
| FY2011 | Dec 31, 2011 | $423.18K | +75.7% |
| FY2010 | Dec 31, 2010 | $240.87K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.14M | +90.9% |
| Q1 FY2026 | Mar 31, 2026 | $1.37M | +0.8% |
| Q4 FY2025 | Dec 31, 2025 | $1.62M | -20.5% |
| Q3 FY2025 | Sep 30, 2025 | $954.00K | -70.6% |
| Q2 FY2025 | Jun 30, 2025 | $1.12M | -74.0% |
| Q1 FY2025 | Mar 31, 2025 | $1.36M | -53.9% |
| Q4 FY2024 | Dec 31, 2024 | $2.04M | -52.3% |
| Q3 FY2024 | Sep 30, 2024 | $3.24M | -22.7% |
| Q2 FY2024 | Jun 30, 2024 | $4.31M | +53.8% |
| Q1 FY2024 | Mar 31, 2024 | $2.95M | -24.5% |
| Q4 FY2023 | Dec 31, 2023 | $4.27M | +29.8% |
| Q3 FY2023 | Sep 30, 2023 | $4.19M | +8.3% |
| Q2 FY2023 | Jun 30, 2023 | $2.80M | +18.6% |
| Q1 FY2023 | Mar 31, 2023 | $3.91M | +36.0% |
| Q4 FY2022 | Dec 31, 2022 | $3.29M | +20.3% |
| Q3 FY2022 | Sep 30, 2022 | $3.87M | +83.9% |
| Q2 FY2022 | Jun 30, 2022 | $2.36M | -7.7% |
| Q1 FY2022 | Mar 31, 2022 | $2.87M | +82.1% |
| Q4 FY2021 | Dec 31, 2021 | $2.73M | +291.5% |
| Q3 FY2021 | Sep 30, 2021 | $2.11M | +1.3% |
| Q2 FY2021 | Jun 30, 2021 | $2.56M | +29.4% |
| Q1 FY2021 | Mar 31, 2021 | $1.58M | +22.9% |
| Q4 FY2020 | Dec 31, 2020 | $698.00K | -27.1% |
| Q3 FY2020 | Sep 30, 2020 | $2.08M | +92.9% |
| Q2 FY2020 | Jun 30, 2020 | $1.98M | +81.1% |
| Q1 FY2020 | Mar 31, 2020 | $1.28M | +46.1% |
| Q4 FY2019 | Dec 31, 2019 | $958.00K | -20.4% |
| Q3 FY2019 | Sep 30, 2019 | $1.08M | -26.6% |
| Q2 FY2019 | Jun 30, 2019 | $1.09M | -2.5% |
| Q1 FY2019 | Mar 31, 2019 | $878.00K | +0.1% |
| Q4 FY2018 | Dec 31, 2018 | $1.20M | +9.1% |
| Q3 FY2018 | Sep 30, 2018 | $1.47M | +5.3% |
| Q2 FY2018 | Jun 30, 2018 | $1.12M | -19.7% |
| Q1 FY2018 | Mar 31, 2018 | $877.00K | -57.7% |
| Q4 FY2017 | Dec 31, 2017 | $1.10M | -98.8% |
| Q3 FY2017 | Sep 30, 2017 | $1.39M | -33.4% |
| Q2 FY2017 | Jun 30, 2017 | $1.39M | – |
| Q1 FY2017 | Mar 31, 2017 | $2.07M | – |
| Q4 FY2016 | Dec 31, 2016 | $93.88M | – |
| Q3 FY2016 | Sep 30, 2016 | $2.09M | – |
See a number that looks wrong?